A transfection-based solution to lentivirus production challenges using a suspension cell line, chemically defined medium, and a process with proven performance at scale. With a platform that can dramatically reduce the time in process development and scale-up in your facilities or by leveraging our CDMO capabilities you can draw on our experience to speed your gene therapy to patients.
VirusExpress™ 293T Lentiviral Production Cells
EX-CELL® CD HEK293 Viral Vector Medium
The VirusExpress™ Lentiviral Production Platform provides a scalable and high-yield lentiviral vector production platform. Transient transfection of a suspension-adapted HEK 293T derived production cells in chemically defined medium (Figure 1) shows proven performance at clinically relevant scale while utilizing a simplified process. Optimal viral titers have been demonstrated in 3 production runs at a 40 L working volume (Figure 2). The VirusExpress Lentiviral Production Platform features not only cells and chemically defined medium but also proven process performance to help you speed your gene therapy to patients.
Figure 1. Cell viability (dashed lined) and cell growth data (solid lines)
Figure 2. Each run exceeded a target functional titer of 1 x 107 TU/mL
and demonstrated successful scale-up to 40 L
Process Development and scale-up for Transient Transfection-Based Lentivirus Production in suspension White Paper.Download White Paper
To place an order, please click on the button below:Place an Order
For information regarding the cell line, medium, and licenses available, please click on the button below:Learn More
The VirusExpress platform offers a transfection-based solution using a suspension cell line, chemically defined medium, and a process with proven performance at scale. Draw on our 30+ years of viral vector manufacturing experience and a platform that can dramatically reduce your process development and scale-up time to speed your therapy to patients. Find out how we can help bring your gene therapy to life.Request More Information